Shanghai Yingjiexin Medical Technology closed a 200 million yuan Series B, about $27.5M, announced November 5. CICC Capital led. Zhuhai Technology Industry Group, Cornerstone Capital, Qiming Venture Partners, Houxin Jiantou and Yingyue Fund joined, and existing backer Photon Venture Capital reinvested.

The company makes high-precision drug delivery hardware: disposable prefilled pens, reusable injection pens and autoinjectors for biologics including GLP-1 drugs, insulin and growth hormone. It says the round funds overseas product registration and capacity, and it has not reported progress on any specific foreign filing.

A pen injector sold into a US biologic program is a constituent part of a combination product, and the drug sponsor carries the application. Registration money at this stage buys design history files, supplier audits and human factors data that a pharma partner can cite, not a clearance of your own.